Tissue Factor Science
Iconic Therapeutics is leveraging its deep insight into the role of tissue factor in inflammation and angiogenesis to develop breakthrough medicines for ophthalmology and oncology indications.
Ophthalmology
With our investigational tissue factor therapeutics, we are pursuing promising opportunities to modify grievous diseases in ophthalmology, including wet age-related macular degeneration (AMD).
Oncology
While tissue factor (TF) overexpression itself is not oncogenic, it facilitates key processes that lead to the development and progression of tumors. We are exploring potential therapeutic agents that target TF across a broad range of solid tumors.
Recent News
April 20, 2021: Dirk Sauer, Ph.D. Joins Iconic Therapeutics’ Board of Directors
December 2, 2020: Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application.
September 15, 2020: Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-In-Class Potential For ICON-2 In Treatment Of Solid Tumors
August 22, 2019: Iconic Therapeutics Signs Ophthalmology Option Agreement